<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIMETREXATE</span><br/>(tri-me-trex'ate)<br/><span class="topboxtradename">Neutrexin<br/></span><b>Classifications:</b> <span class="classification">antimetabolite, antifolate agent</span><br/><b>Prototype: </b>Methotrexate<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Antimetabolite and folic acid antagonist. Blocks folinic acid (active form of folic acid) participation in nucleic acid synthesis,
         thereby interfering with miotic process. Acts as a dihydrofolate reductase (DHFR) inhibitor in a similar manner to methotrexate.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Disrupts DNA, RNA, and protein synthesis, with consequent cell death.</p>
<h1><a name="uses">Uses</a></h1>
<p>Used with concurrent leucovorin administration, as an alternate therapy for moderate-to-severe <i>Pneumocystis carinii</i> pneumonia (PCP) in immunocompromised patients, including AIDS patients.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Advanced non-small cell lung cancer, metastatic cancer of the head and neck, metastatic colorectal adenocarcinoma, pancreatic
         carcinoma.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to trimetrexate, leucovorin, or methotrexate; profound myelosuppression; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Seizures; mild myelosuppression; severe kidney or liver dysfunction; hypoalbuminemia or hypoproteinemia; concomitant use of
         myelosuppressive, hepatotoxic, or renal toxic drugs; previous radiation of bone marrow or extensive chemotherapy with myelotoxic
         agents. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">
<i>Pneumocystis carinii</i> Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg/m<sup>2</sup>/d prepared as the IV solution has been given orally to AIDS patients with PCP <span class="rdroute">IV</span> 45 mg/m<sup>2</sup> once daily by IV infusion over 6090 min with concurrent leucovorin 20 mg/m<sup>2</sup> q6h (IV or PO, trimetrexate times 21 d and leucovorin times 24 d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Reconstitute 25 mg with 2 mL of D5W or sterile water for injection to yield 12.5 mg/mL. Allow 30 s for complete dissolution.
                  Manufacturer recommends filtering (0.22 micron) reconstituted solution prior to dilution. Further dilute with 10100
                  mL of D5W to a final concentration of 0.252 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over 6090 min. Flush IV line with at least 10 mL of D5W before and after administering trimetrexate.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive &amp; Y-site:</span>
<span class="classification">chloride-containing solutions</span> (including <b>sodium chloride</b>), <b>foscarnet,</b>
<b>indomethacin.</b>
</p>
<ul>
<li>Wash with soap and water immediately if drug contacts skin.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solution at room temperature or refrigerated for 24 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span>
<span class="speceff-both">Myelosuppression, granulocytopenia, thrombocytopenia</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, stomatitis</span>. <span class="typehead">Skin:</span> Erythematous rash with posteruption hyperpigmentation. <span class="typehead">Metabolic:</span> Mild transient elevations in serum creatinine and liver function tests. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Mild increases in <span class="alt">serum creatinine</span> and <span class="alt">liver function tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cimetidine,</b>
<b>erythromycin,</b>
<b>fluconazole</b> (and other <span class="classification">azole antifungal agents</span>) may increase trimetrexate levels and toxicity. <b>Rifabutin,</b>
<b>rifampin</b> may decrease trimetrexate levels. <b>Zidovudine</b> may cause additive hematologic toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 44% absorbed from GI tract. <span class="typehead">Onset:</span> 3 d. <span class="typehead">Distribution:</span> Very low CSF concentrations; distributes into lung tissue; 98% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine and feces. <span class="typehead">Half-Life:</span> 1517 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC at least twice a week during therapy. Myelosuppression nadir occurs around day 8. Monitor kidney and
            liver functions; impaired functioning may indicate need for dosage reduction.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn potential adverse effects and report those that are bothersome.</li>
<li>Understand that myelosuppression is the primary dose-limiting adverse effect.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>